T-Cell Immunotherapy – Revolutionizing Cancer Treatment

RNCOS has announced the addition of “T-Cell Immunotherapy for Cancer - Pipeline Analysis” report to its offerings. This report will provide widespread research on the use of T-Cell Immunotherapy for cancer.

The T-cell immunotherapy market is growing pervasively and will continue the trend in the coming years owing to the growing incidences of cancer all across the globe attributing to the changing lifestyle and unhealthy eating habits. In 2015, approximately 15.2 Million incidences of cancer were reported in the world. This number is forecast to reach 19.3 Million and 21.6 Million by 2025 and 2030, respectively.

According to our report, “T-Cell Immunotherapy for Cancer – Pipeline Analysis”, conventional treatment options such as chemotherapy and radiation therapy have aided in slowing down the progression of cancer. However, there is no complete treatment for the disease in the market. Furthermore, these therapeutic options cause numerous side effects such as hair loss, weight loss, abnormal blood count and nausea. These limitations have created the need for innovative treatment option for cancer with minimal side effects.

Advancements in technology have helped in the development of novel treatment options for cancer which is one of the leading causes of mortality worldwide. One such innovative therapy is the T-cell immunotherapy. This therapy, also known as adoptive cell transfer, makes use of patient’s own immune system. There are three approaches to T-cell immunotherapy- CAR T-cell therapy, TCR therapy and TIL therapy. Among the three types, CAR T is the most studied and widely used technology by companies. In CAR T-cell therapy, patient’s T-cells are collected from the blood. These cells are genetically modified and then infused into the cancer patient for treatment.

CAR T-cell therapy is also the first type of T-cell immunotherapy to receive approval from the USFDA for commercial use. In August 2017, Novartis received approval in the US for the first T-cell immunotherapy by the name of Kymriah. Similarly, Kite Pharma-A Gilead Company also received approval for Yescarta in October 2017. The biopharmaceutical companies are also developing strong pipeline of T-cell immunotherapies. All these therapies, once approved are poised to push the growth of market for T-cell immunotherapy for cancer.

Benefits from the report:

• Extensive information related to upcoming product pipeline
• New opportunities in global market
• Suitable areas of investment
• Major competitors in the market
• Areas of benefit for existing/new players

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm


Contact Details

Company Name: RNCOS E-Services Pvt. Ltd.
Issued By: Shushmul Maheshwari
Phone: 1204224700
Address: G-199, Sector-63
City: Noida
State: Uttar Pradesh
Zip: 201301
Country: India
Website: Visit the website

Keywords : T-Cell Immunotherapy for Cancer, t cell immunotherapy market, t cell immunotherapy market report, t cell immunotherapy market research, t cell immunotherapy market forecast, t cell immunotherapy market analysis,

by Shushmul Maheshwari (few months ago!)

Latest Press Releases

The Mad Hatter Now Offer a Full Line of Hearth Products and Full Line of Grills

Diabetes Insulin Delivery Pens Market Research Report 2018

Dr Kapadia Provides Tips to Patients Interested in Hair Transplant Procedures

love vashikaran specialist

Solar Blanket Sales Market Report 2018

Spring Bottled Water Market Insights, Forecast to 2025

Biochemical Incubator Sales Market Report 2018

Quinine Sulphate Sales Market Report 2018

Automotive Chassisc System Market Insights, Forecast to 2025

2,6-Dicarboxypyridine market size in key regions like North America, Europe, Asia Pacific an..

Remove this press release ?

Due to extra work required to remove the press-releases we have started charging $1.99 for press release removal.

Your press release will be removed in 24 hours, once the payment has been received.

Search Press Release
e.g. Business, Computer, etc.